| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.26B | 2.09B | 1.75B | 1.51B | 1.38B | 997.80M |
| Gross Profit | 508.60M | 448.30M | 359.40M | 335.60M | 395.00M | 263.50M |
| EBITDA | 340.60M | 171.20M | 257.40M | 215.90M | 274.90M | 151.60M |
| Net Income | 43.40M | 16.70M | 17.60M | 11.80M | 101.80M | 25.80M |
Balance Sheet | ||||||
| Total Assets | 2.32B | 2.14B | 1.94B | 1.83B | 1.68B | 1.11B |
| Cash, Cash Equivalents and Short-Term Investments | 89.40M | 82.80M | 64.40M | 49.10M | 277.90M | 86.80M |
| Total Debt | 1.42B | 1.24B | 1.00B | 940.00M | 764.60M | 367.40M |
| Total Liabilities | 1.83B | 1.65B | 1.41B | 1.32B | 1.12B | 627.40M |
| Stockholders Equity | 467.40M | 464.80M | 496.50M | 474.70M | 517.60M | 448.00M |
Cash Flow | ||||||
| Free Cash Flow | 157.30M | 139.60M | 94.50M | 29.60M | 114.50M | 83.50M |
| Operating Cash Flow | 281.30M | 261.90M | 205.00M | 170.20M | 216.70M | 156.00M |
| Investing Cash Flow | -289.80M | -134.70M | -119.80M | -184.80M | -333.60M | -126.30M |
| Financing Cash Flow | 14.40M | -108.00M | -73.70M | -24.30M | 164.10M | -14.10M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | kr11.97B | 18.10 | ― | 1.54% | 2.96% | 73.50% | |
| ― | €16.70B | 47.26 | 4.63% | ― | 17.13% | ― | |
| ― | kr2.42B | 9.94 | 7.53% | 2.14% | 2.11% | 92.69% | |
| ― | kr32.54B | ― | ― | ― | ― | ― | |
| ― | €9.91B | 16.83 | 12.76% | 1.73% | 8.38% | 21.07% | |
| ― | kr39.18B | 81.00 | ― | 0.56% | 15.92% | 82.51% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Medicover AB announced additional interim results from the DART clinical study at Oslo University Hospital, highlighting the effectiveness of its MRD assay in predicting disease progression in non-small cell lung cancer. The study, presented at the European Society for Medical Oncology Congress, strengthens the clinical validation of Medicover’s MRD assay, marking a significant step towards its commercialisation in 2026 and expansion into other therapeutic areas.
The most recent analyst rating on ($SE:MCOV.B) stock is a Hold with a SEK267.00 price target. To see the full list of analyst forecasts on Medicover AB stock, see the SE:MCOV.B Stock Forecast page.
Medicover AB has announced that it will release its Q3 2025 financial report on November 5, 2025. The company will host a conference call for media, financial analysts, and investors, where CEO John Stubbington and CFO Anand Patel will present the report, followed by a Q&A session. This announcement is significant as it provides stakeholders with insights into the company’s financial performance and strategic direction.
The most recent analyst rating on ($SE:MCOV.B) stock is a Hold with a SEK267.00 price target. To see the full list of analyst forecasts on Medicover AB stock, see the SE:MCOV.B Stock Forecast page.
Medicover AB has announced the composition of its nomination committee for the 2026 Annual General Meeting, which includes representatives from Celox Holding AB, NG Invest Beta AB, Fjärde AP-Fonden, and Swedbank Robur Fonder. This announcement is significant as it sets the stage for shareholder engagement and governance planning ahead of the AGM scheduled for April 2026.
The most recent analyst rating on ($SE:MCOV.B) stock is a Hold with a SEK265.00 price target. To see the full list of analyst forecasts on Medicover AB stock, see the SE:MCOV.B Stock Forecast page.
Medicover AB has had its greenhouse gas emissions reduction targets validated by the Science Based Targets Initiative (SBTi). The company aims to significantly reduce its scope 1, 2, and 3 emissions by 2030 and 2050, aligning with its goal of achieving net zero emissions by 2050. This commitment underscores Medicover’s dedication to sustainability while expanding its healthcare services.
The most recent analyst rating on ($SE:MCOV.B) stock is a Hold with a SEK281.00 price target. To see the full list of analyst forecasts on Medicover AB stock, see the SE:MCOV.B Stock Forecast page.
Medicover AB has updated its Social Finance Framework to align with the latest International Capital Market Association and Loan Market Association principles. This revision emphasizes Medicover’s commitment to enhancing healthcare accessibility and promoting employee wellbeing, aiming to combine financial strength with social impact. The updated framework, reviewed by DNV, will guide the issuance of social bonds and loans to support eligible projects.
The most recent analyst rating on ($SE:MCOV.B) stock is a Hold with a SEK297.00 price target. To see the full list of analyst forecasts on Medicover AB stock, see the SE:MCOV.B Stock Forecast page.